These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 25076246)

  • 1. Low expression of excision repair cross-complementation group-1 protein predicts better outcome in patients with locally advanced nasopharyngeal cancer treated with concurrent chemoradiotherapy.
    Zhang Z; Jiang C; Hu L
    Tumori; 2014; 100(3):328-32. PubMed ID: 25076246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of excision repair cross- complementation group 1 expression in locoregionally advanced nasopharyngeal carcinoma receiving cisplatin-based concurrent chemoradiotherapy.
    Wang D; Zhou J; Zheng J; Zhang J; Chen Y; Li W; Wang R
    Cancer Biomark; 2018; 21(4):875-881. PubMed ID: 29439312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between ERCC1 expression and concurrent chemotherapy and radiotherapy in patients with locally advanced nasopharyngeal cancer.
    Liang R; Lin Y; Liu ZH; Liao XL; Yuan CL; Liao SN; Li YQ
    Genet Mol Res; 2015 May; 14(2):5804-11. PubMed ID: 26125779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of ERCC1 and TUBB3 in locally advanced cervical squamous cell cancer and its correlation with different therapeutic regimens.
    Zwenger AO; Grosman G; Iturbe J; Leone J; Vallejo CT; Leone JP; Verdera PP; Pérez JE; Leone BA
    Int J Biol Markers; 2015 Jul; 30(3):e301-14. PubMed ID: 26165688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can the analysis of ERCC1 expression contribute to individualized therapy in nasopharyngeal carcinoma?
    Chan SH; Cheung FM; Ng WT; Choi CW; Cheung KN; Yiu KH; Lee AW
    Int J Radiat Oncol Biol Phys; 2011 Apr; 79(5):1414-20. PubMed ID: 20605357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of excision repair cross-complementation group 1 in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy.
    Shen C; Chen L; Fu J; Lin H
    J Cancer Res Ther; 2016 Oct; 12(Supplement):72-75. PubMed ID: 27721259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy.
    Sun JM; Ahn MJ; Park MJ; Lee HY; Ahn JS; Lee S; Kang G; Han J; Son YI; Baek CH; Ahn YC; Park K
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(3):655-60. PubMed ID: 21621119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of BRCA1 and ERCC1 as predictive clinical outcome after radiochemotherapy in patients with locoregionally moderate-advanced nasopharyngeal carcinoma.
    Xu S; Yu Y; Rong J; Hu D; Zhang L; Fu S; Yang H; Fan J; Yang L; Wu J
    Oncotarget; 2017 May; 8(19):31355-31367. PubMed ID: 28404895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with nasopharyngeal cancer.
    Lee HW; Hwang YH; Han JH; Choi JH; Kang SY; Jeong SH; Ann MS; Oh YT; Kim JH; Kim CH; Sheen SS
    Oral Oncol; 2010 Mar; 46(3):209-13. PubMed ID: 20153243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
    Azuma K; Sasada T; Kawahara A; Hattori S; Kinoshita T; Takamori S; Ichiki M; Imamura Y; Ikeda J; Kage M; Kuwano M; Aizawa H
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):565-73. PubMed ID: 19123003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
    Hwang IG; Ahn MJ; Park BB; Ahn YC; Han J; Lee S; Kim J; Shim YM; Ahn JS; Park K
    Cancer; 2008 Sep; 113(6):1379-86. PubMed ID: 18623378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy.
    Kim KH; Do IG; Kim HS; Chang MH; Kim HS; Jun HJ; Uhm J; Yi SY; Lim DH; Ji SH; Park MJ; Lee J; Park SH; Kwon GY; Lim HY
    APMIS; 2010 Dec; 118(12):941-8. PubMed ID: 21091775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy.
    Sodja E; Knez L; Kern I; Ovčariček T; Sadikov A; Cufer T
    Eur J Cancer; 2012 Dec; 48(18):3378-85. PubMed ID: 22795264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer.
    Fujii T; Toyooka S; Ichimura K; Fujiwara Y; Hotta K; Soh J; Suehisa H; Kobayashi N; Aoe M; Yoshino T; Kiura K; Date H
    Lung Cancer; 2008 Mar; 59(3):377-84. PubMed ID: 17905465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy.
    Huang PY; Li Y; Mai HQ; Luo RZ; Cai YC; Zhang L
    Oral Oncol; 2012 Oct; 48(10):964-968. PubMed ID: 22571922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
    Handra-Luca A; Hernandez J; Mountzios G; Taranchon E; Lacau-St-Guily J; Soria JC; Fouret P
    Clin Cancer Res; 2007 Jul; 13(13):3855-9. PubMed ID: 17606717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERCC1 mRNA levels can predict the response to cisplatin-based concurrent chemoradiotherapy of locally advanced cervical squamous cell carcinoma.
    Bai ZL; Wang YY; Zhe H; He JL; Hai P
    Radiat Oncol; 2012 Dec; 7():221. PubMed ID: 23259415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival.
    Zimling ZG; Sørensen JB; Gerds TA; Bech C; Andersen CB; Santoni-Rugiu E
    J Thorac Oncol; 2012 Jan; 7(1):249-56. PubMed ID: 22031231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.
    Bellmunt J; Paz-Ares L; Cuello M; Cecere FL; Albiol S; Guillem V; Gallardo E; Carles J; Mendez P; de la Cruz JJ; Taron M; Rosell R; Baselga J;
    Ann Oncol; 2007 Mar; 18(3):522-8. PubMed ID: 17229776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.
    Bauman JE; Austin MC; Schmidt R; Kurland BF; Vaezi A; Hayes DN; Mendez E; Parvathaneni U; Chai X; Sampath S; Martins RG
    Br J Cancer; 2013 Oct; 109(8):2096-105. PubMed ID: 24064970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.